Evidence map›Paper›PMID 33804312›Full record

ArticleJournal of clinical medicine2021

Validation of the Monitoring Efficacy of Neurogenic Bowel Treatment on Response (MENTOR) Tool in a Japanese Rehabilitation Setting.

Masashi Nomi, Atsushi Sengoku, Klaus Krogh, Anton Emmanuel, Albert Bohn Christiansen

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Masashi NomiDepartment of Urology, Hyogo Prefectural Central Rehabilitation Hospital, Hyogo 651-2181, Japan.ORCID 0000-0003-3142-9363
Atsushi SengokuDepartment of Urology, Hyogo Prefectural Central Rehabilitation Hospital, Hyogo 651-2181, Japan.
Klaus KroghDepartment of Hepatology and Gastroenterology, Aarhus University Hospital, 8000 Aarhus, Denmark.
Anton EmmanuelGI Physiology Unit, University College Hospital, London NW1 2BU, UK.
Albert Bohn ChristiansenMedical Affairs, Coloplast A/S, 2970 Humlebaek, Denmark.

Funding

Coloplast A/S None
6 · The paper itself

Abstract

STUDY

designProspective observational study.

objectiveTo validate the Monitoring Efficacy of NBD Treatment On Response (MENTOR) tool in individuals with a spinal cord injury (SCI) or spina bifida, suffering from neurogenic bowel dysfunction (NBD) in a rehabilitation center in Japan.

methodsFirst, the MENTOR tool was translated from English to Japanese using a validated translation process. Second, the MENTOR tool was validated in a rehabilitation clinic in Japan. Participants completed the MENTOR tool prior to a consultation with an expert physician. According to the results of the tool, each participant was allocated to one of three categories regarding change in treatment: "adequately treated," "further discussion," and "recommended change." The results of the MENTOR tool were compared with the treatment decision made by an expert physician, who was blinded to the results of the MENTOR tool.

resultsA total of 60 participants completed the MENTOR tool. There was an acceptable concordance between individuals allocated as respectively, being adequately treated (100%) and recommended change in treatment (61%) and the physicians' decision on treatment. The concordance was lower for individuals allocated as requiring further discussion (48%).

conclusionsIn this study the MENTOR tool was successfully validated in a Japanese rehab setting. The tool will help identify individuals with SCI that need further treatment of their NBD symptoms.

Indexed as

neurogenic bowelspinal cord injurytreatment assessment

Identifiers

PMID33804312
PMCPMC7957617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.